Free Trial

Viatris (VTRS) Competitors

Viatris logo
$8.48 -0.40 (-4.50%)
Closing price 04:00 PM Eastern
Extended Trading
$8.48 -0.01 (-0.06%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VTRS vs. ARGX, BNTX, ONC, TEVA, SMMT, ITCI, GMAB, RDY, MRNA, and QGEN

Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

Viatris vs.

Viatris (NASDAQ:VTRS) and argenx (NASDAQ:ARGX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

argenx received 640 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 67.52% of users gave argenx an outperform vote while only 34.85% of users gave Viatris an outperform vote.

CompanyUnderperformOutperform
ViatrisOutperform Votes
23
34.85%
Underperform Votes
43
65.15%
argenxOutperform Votes
663
67.52%
Underperform Votes
319
32.48%

Viatris has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Viatris presently has a consensus target price of $10.50, suggesting a potential upside of 23.82%. argenx has a consensus target price of $698.11, suggesting a potential upside of 19.35%. Given Viatris' higher probable upside, equities analysts plainly believe Viatris is more favorable than argenx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viatris
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75
argenx
0 Sell rating(s)
1 Hold rating(s)
20 Buy rating(s)
2 Strong Buy rating(s)
3.04

In the previous week, Viatris had 10 more articles in the media than argenx. MarketBeat recorded 32 mentions for Viatris and 22 mentions for argenx. argenx's average media sentiment score of 1.19 beat Viatris' score of 0.01 indicating that argenx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viatris
0 Very Positive mention(s)
2 Positive mention(s)
25 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
argenx
16 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Viatris has higher revenue and earnings than argenx. Viatris is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viatris$14.33B0.69$54.70M-$3.17-2.68
argenx$2.58B13.84-$295.05M$16.2136.09

79.9% of Viatris shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 2.4% of argenx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

argenx has a net margin of -2.11% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat argenx's return on equity.

Company Net Margins Return on Equity Return on Assets
Viatris-5.87% 16.46% 7.09%
argenx -2.11%-1.45%-1.29%

Summary

argenx beats Viatris on 10 of the 19 factors compared between the two stocks.

Get Viatris News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTRS vs. The Competition

MetricViatrisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$9.95B$6.48B$5.35B$8.38B
Dividend Yield5.46%2.66%5.22%4.10%
P/E Ratio-11.468.9226.8419.71
Price / Sales0.69250.96391.39116.98
Price / Cash2.1165.8538.2534.62
Price / Book0.506.466.794.50
Net Income$54.70M$143.98M$3.23B$248.18M
7 Day Performance0.71%3.04%4.07%1.14%
1 Month Performance12.02%7.44%12.52%15.18%
1 Year Performance-22.63%-2.46%16.83%6.55%

Viatris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTRS
Viatris
2.0946 of 5 stars
$8.48
-4.5%
$10.50
+23.8%
-19.8%$9.95B$14.33B-11.4637,000Trending News
Gap Up
ARGX
argenx
3.3157 of 5 stars
$560.90
+2.0%
$697.94
+24.4%
+59.9%$34.25B$2.19B-637.39650Positive News
Gap Up
High Trading Volume
BNTX
BioNTech
2.8587 of 5 stars
$97.27
+4.9%
$142.73
+46.7%
+10.0%$23.34B$2.75B-46.323,080News Coverage
ONC
Beigene
2.721 of 5 stars
$233.25
+0.5%
$319.00
+36.8%
N/A$23.07B$4.18B-28.319,000
TEVA
Teva Pharmaceutical Industries
3.3111 of 5 stars
$17.92
+5.8%
$24.43
+36.4%
-0.4%$20.31B$16.62B-12.3636,800Options Volume
SMMT
Summit Therapeutics
3.1907 of 5 stars
$25.26
+5.4%
$37.40
+48.1%
+437.2%$18.76B$700,000.00-90.21110Positive News
ITCI
Intra-Cellular Therapies
0.8721 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.4467 of 5 stars
$19.93
+2.9%
$39.17
+96.5%
-31.5%$12.78B$21.64B11.451,660News Coverage
Positive News
RDY
Dr. Reddy's Laboratories
2.3333 of 5 stars
$13.93
+3.9%
$17.00
+22.1%
+5.3%$11.62B$311.31B22.1724,800Positive News
Gap Up
MRNA
Moderna
4.4677 of 5 stars
$25.70
+6.0%
$53.95
+109.9%
-80.2%$9.94B$3.14B-2.773,900Trending News
QGEN
Qiagen
4.0353 of 5 stars
$42.92
+2.5%
$48.42
+12.8%
-3.4%$9.54B$1.98B119.526,030Positive News

Related Companies and Tools


This page (NASDAQ:VTRS) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners